ABCL – AbCellera Biologics Inc.
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ABCL
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ABCL — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
19.19
Margin Of Safety %
Put/Call OI Ratio
0.38
EPS Next Q Diff
0.01
EPS Last/This Y
-0.16
EPS This/Next Y
-0.07
Price
6.94
Target Price
10.75
Analyst Recom
1
Performance Q
Upside
-201.3%
Beta
1.21
Ticker: ABCL
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ABCL | 6.51 | 0.32 | 0.49 | 188476 |
| 2026-07-14 | ABCL | 6.74 | 0.33 | 0.38 | 188846 |
| 2026-07-15 | ABCL | 6.73 | 0.32 | 0.26 | 189752 |
| 2026-07-16 | ABCL | 6.16 | 0.32 | 0.14 | 189061 |
| 2026-07-17 | ABCL | 6.47 | 0.32 | 0.25 | 186702 |
| 2026-07-20 | ABCL | 5.8 | 0.33 | 0.10 | 145313 |
| 2026-07-21 | ABCL | 5.97 | 0.37 | 0.51 | 139475 |
| 2026-07-22 | ABCL | 5.73 | 0.38 | 0.27 | 143965 |
| 2026-07-23 | ABCL | 5.67 | 0.38 | 0.50 | 143799 |
| 2026-07-24 | ABCL | 5.3 | 0.38 | 0.18 | 144069 |
| 2026-07-27 | ABCL | 5.24 | 0.38 | 0.27 | 144678 |
| 2026-07-28 | ABCL | 5.3 | 0.38 | 0.19 | 145206 |
| 2026-07-29 | ABCL | 5.39 | 0.38 | 0.08 | 145599 |
| 2026-07-30 | ABCL | 5.7 | 0.37 | 0.05 | 146943 |
| 2026-07-31 | ABCL | 5.72 | 0.37 | 0.05 | 147945 |
| 2026-08-03 | ABCL | 5.82 | 0.37 | 0.11 | 148773 |
| 2026-08-04 | ABCL | 6.1 | 0.37 | 0.17 | 148111 |
| 2026-08-05 | ABCL | 5.93 | 0.37 | 0.18 | 148494 |
| 2026-08-06 | ABCL | 6.53 | 0.36 | 0.43 | 149191 |
| 2026-08-07 | ABCL | 6.79 | 0.38 | 0.22 | 151806 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ABCL | 6.51 | -37.5 | - | -0.65 |
| 2026-07-14 | ABCL | 6.74 | -37.5 | - | -0.65 |
| 2026-07-15 | ABCL | 6.73 | -37.5 | - | -0.65 |
| 2026-07-16 | ABCL | 6.16 | -37.5 | - | -0.65 |
| 2026-07-17 | ABCL | 6.47 | -30.6 | - | -0.63 |
| 2026-07-20 | ABCL | 5.79 | -30.6 | - | -0.63 |
| 2026-07-21 | ABCL | 5.96 | 0.0 | - | -0.63 |
| 2026-07-22 | ABCL | 5.73 | 0.0 | - | -0.63 |
| 2026-07-23 | ABCL | 5.67 | 0.0 | - | -0.63 |
| 2026-07-24 | ABCL | 5.30 | 0.0 | - | -0.63 |
| 2026-07-27 | ABCL | 5.26 | 0.0 | - | -0.63 |
| 2026-07-28 | ABCL | 5.30 | 0.0 | - | -0.63 |
| 2026-07-29 | ABCL | 5.39 | 0.0 | - | -0.63 |
| 2026-07-30 | ABCL | 5.70 | 0.0 | - | -0.63 |
| 2026-07-31 | ABCL | 5.71 | -37.5 | - | -0.65 |
| 2026-08-03 | ABCL | 5.82 | -37.5 | - | -0.65 |
| 2026-08-04 | ABCL | 5.82 | -37.5 | - | -0.65 |
| 2026-08-05 | ABCL | 5.94 | -37.5 | - | -0.65 |
| 2026-08-06 | ABCL | 6.52 | -37.5 | - | -0.65 |
| 2026-08-07 | ABCL | 6.94 | -37.5 | - | -0.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ABCL | 0.00 | 8.10 | 20.66 |
| 2026-07-14 | ABCL | 0.00 | 8.10 | 20.66 |
| 2026-07-15 | ABCL | 0.00 | 8.10 | 20.66 |
| 2026-07-16 | ABCL | 0.00 | 8.10 | 20.66 |
| 2026-07-17 | ABCL | 0.00 | 8.10 | 20.66 |
| 2026-07-20 | ABCL | 0.00 | 8.11 | 20.66 |
| 2026-07-21 | ABCL | 0.00 | 8.11 | 20.66 |
| 2026-07-22 | ABCL | 0.00 | 8.11 | 20.66 |
| 2026-07-23 | ABCL | 0.00 | 8.11 | 20.66 |
| 2026-07-24 | ABCL | 0.00 | 8.11 | 20.66 |
| 2026-07-27 | ABCL | 0.00 | 8.96 | 19.19 |
| 2026-07-28 | ABCL | 0.00 | 8.96 | 19.19 |
| 2026-07-29 | ABCL | 0.00 | 8.96 | 19.19 |
| 2026-07-30 | ABCL | 0.00 | 8.96 | 19.19 |
| 2026-07-31 | ABCL | 0.00 | 8.96 | 19.19 |
| 2026-08-03 | ABCL | 0.00 | 2.77 | 19.19 |
| 2026-08-04 | ABCL | 0.00 | 2.77 | 19.19 |
| 2026-08-06 | ABCL | 0.00 | 2.77 | 19.19 |
| 2026-08-07 | ABCL | 0.00 | 2.77 | 19.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ABCL
589 360 ]
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.17
Avg. EPS Est. Next Quarter
-0.17
Insider Transactions
Institutional Transactions
2.77
Beta
1.21
Average Sales Estimate Current Quarter
7
Average Sales Estimate Next Quarter
7
Fair Value
Quality Score
23
Growth Score
26
Sentiment Score
93
Actual DrawDown %
69.3
Max Drawdown 5-Year %
-91
Target Price
10.75
P/E
Forward P/E
PEG
P/S
32.11
P/B
2.37
P/Free Cash Flow
EPS
-0.54
Average EPS Est. Cur. Y
-0.65
EPS Next Y. (Est.)
-0.72
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-248.83
Relative Volume
0.8
Return on Equity vs Sector %
-45.7
Return on Equity vs Industry %
-29.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ABCL
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ABCL
589 450 ]
◆
ABCL
Healthcare
$6.93
📉
N/A
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
12/20
Pullback
4/25
Volume
7/15
Valuation
9/20
TP/AR
4/10
Options
8/10
RSI
61.7
Range 1M
65.8%
Sup Dist
14.7%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
10/25
Growth
4/30
Estimates
2/20
Inst/Vol
4/15
Options
8/10
EPS Yr
-35.7%
52W%
70.7%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+55.1% upside
Quality
5/30
Valuation
12/30
Growth
1/25
Stability
7/10
LT Trend
3/5
Upside
+55.1%
Quality
23
Click a card to see score breakdown
Full Analysis →
ABCL — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 562
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
[News_ABCL
_Stock]
stock quote shares ABCL – AbCellera Biologics Inc. Stock Price stock today
news today ABCL – AbCellera Biologics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABCL – AbCellera Biologics Inc. yahoo finance google finance
stock history ABCL – AbCellera Biologics Inc. invest stock market
stock prices ABCL
premarket after hours
ticker ABCL
fair value insiders trading